Digital Health Partnerships: What Pharma Executives Need to Evaluate

The Digital Health Partnership Landscape in 2026

The digital health partnership landscape pharma executives navigate today is materially different from the one that existed five years ago. The early wave of digital therapeutic partnerships — Pear Therapeutics, Akili, Click Therapeutics — produced as many cautionary tales as success stories, and pharma’s appetite has correspondingly matured. The current wave is broader, more integrated, and more strategically deliberate.

Five categories dominate the current pipeline. Digital therapeutics, where prescription software is paired with or differentiates a pharmaceutical product. Companion diagnostics and biomarker tools, where digital capability supports patient selection and stratification. Real-world evidence platforms, where pharma accesses curated patient data and outcomes signals. AI-enabled clinical tools, where pharma deploys partner technology in clinical operations or downstream commercial activities. And patient engagement ecosystems, where pharma supports adherence, education, and outcome capture through partner-built digital experiences.

Each category has different value capture mechanics, different regulatory exposure, and different partnership structures that work — and each has its own pattern of failure. A blanket evaluation framework misses category-specific signal; a category-aware framework catches it. The first step in any serious evaluation is naming which category the deal sits in and what the category-specific success patterns require.

Capital flowing into the space remains substantial despite a more selective pharma posture. Digital health funding rounds in 2025 surfaced over forty pharma-affiliated investments and partnerships at material scale, and the deal pace continues into 2026. The question for pharma executives isn’t whether to participate — most enterprise pharma organizations are already several partnerships in. The question is whether the next deal is a real strategic move or another addition to a portfolio that already has more partnerships than the organization can effectively manage.

Why Most Partnerships Underperform

Partnership failure in digital health follows a small number of recurring patterns. Naming them helps executives recognize the pattern in the deal in front of them, often before the deal closes.

Strategic ambiguity at the top. The pharma sponsor and the partner have different ideas about what the deal is for. The pharma side sees it as a hedge or an option; the partner sees it as a commercial path. The misalignment is rarely surfaced explicitly because both sides benefit from signing, but it surfaces under stress when commercial decisions force a choice. Partnerships built on ambiguity rarely survive the first quarter when interests diverge — and they always diverge eventually.

No real economic case. The deal is justified by strategic narrative rather than by an economic case anyone has stress-tested. When the partnership produces revenue or savings below expectations, there’s no baseline to measure against, no triggers for course correction, and no defensible argument for sustained investment when budget pressure mounts. The partnership drifts into the maintenance category and slowly starves.

Underestimated integration cost. Pharma underestimates what it takes to integrate the partner’s capability into its own systems, processes, and regulated workflows. The partnership is signed assuming integration is straightforward; eighteen months in, the integration team is two-thirds the size of the original deal team and the timelines have slipped twice. The capability the deal was built around isn’t accessible to the people who needed it.

Regulatory or quality misfit. The partner was building for a less regulated market — consumer wellness, employer health, payer-driven care — and the documentation, validation evidence, and operational practices don’t meet pharma standards. The partner has to retrofit pharma-grade discipline mid-relationship, which slows everything and raises costs that weren’t priced into the original deal.

Vendor instability. The partner pivots, runs out of capital, or gets acquired by a player whose strategic direction doesn’t match pharma’s needs. The partnership terms didn’t anticipate the discontinuity and the recovery work consumes more energy than the partnership was supposed to deliver.

Strategic Fit: The Threshold Question

Strategic fit is the threshold question. If the partnership doesn’t pass strategic fit, no amount of careful contract drafting recovers it. A partnership that’s strategically loose creates ongoing friction; a partnership that’s strategically tight survives execution stumbles that would kill a weaker deal.

Three tests for strategic fit that hold up well in practice:

The theory-of-value test is the most powerful and the most often skipped. Executives accept narrative justification — “this strengthens our digital position in oncology” — without pressing for what the partnership actually changes about the company’s competitive trajectory. The discipline that pays back is forcing the question: in twenty-four months, what is true about this organization that wouldn’t be true without this partnership? If the answer is generic, the partnership is generic. Generic partnerships rarely justify the management overhead they consume.

Portfolio coherence is the second discipline. A pharma organization with seventeen digital health partnerships across thirteen functions does not have a digital strategy — it has a collection of decisions. Each partnership is justifiable in isolation; the portfolio as a whole is incoherent. Each new deal should be evaluated against the question: does this strengthen a deliberate portfolio, or add to an unmanaged accumulation? When the answer points to accumulation, the better executive move is often to consolidate or exit existing partnerships before adding another.

Regulatory and Quality Exposure

Regulatory and quality exposure is the second non-negotiable evaluation dimension, and the one most consistently underestimated by pharma executives without QA backgrounds. A digital health partner becomes part of pharma’s regulated surface in ways the deal team often doesn’t fully appreciate at signing.

Three exposure dimensions deserve particular attention. The partner’s product itself may have regulatory status — FDA-cleared, CE-marked, or in active submission — and that status may be impacted by changes pharma needs the partner to make. The partner’s data and outputs may be used in regulated contexts within pharma — pharmacovigilance, real-world evidence submissions, label expansions — and the partner’s documentation has to support those uses to inspector standards. The partner’s operational practices may need to align with pharma’s own quality system in ways that require contract terms most digital health vendors weren’t expecting.

The corrective for regulatory exposure isn’t to walk away from every partner whose practices don’t immediately match pharma standards — that would eliminate most of the innovative partners worth pursuing. The corrective is to evaluate the gap honestly, price the remediation cost into the deal, and either contract for the partner to close the gap on a defined timeline or accept that the partnership is bounded to use cases where the gap doesn’t matter. Treating regulatory fit as a binary pass-fail when it’s actually a spectrum loses partnerships that could have been valuable; treating it as a soft preference creates regulatory exposure that surfaces under inspection.

Data Rights, IP, and Commercial Terms

Data and IP terms are where partnership economics are determined long before commercial outcomes are visible. Pharma organizations consistently leave value on the table by accepting partner-favorable defaults rather than negotiating the terms that match the deal’s actual strategic intent.

Five data and IP questions deserve explicit treatment in every digital health partnership:

• Training and learning rights. Can the partner use data generated through the partnership to improve its core product, including for the benefit of competitors? If yes, what’s the protection mechanism for sensitive pharma-specific value?
• Output ownership and reuse. Who owns analyses, models, and derived insights? Can pharma reuse them across the portfolio, or are they bound to the original use case?
• Patient-level data residency. Where does data live, who can access it, and what happens at termination? Pharma organizations have increasingly little appetite for arrangements where patient-level data is held in jurisdictions or under terms they can’t fully control.
• Exclusivity and competition. Does the partnership preclude the partner from offering similar capability to competitors? In what scope, and for how long? Most digital health partners resist exclusivity; the negotiation question is whether bounded exclusivity in a specific therapeutic area or use case is achievable.
• Termination and continuity. What happens to data, models, and integration when the partnership ends? Inadequate termination terms create durable lock-in that distorts economics across the partnership lifecycle.

Pricing structure deserves comparable attention. Subscription, per-use, milestone-based, and revenue-share models each have different incentive alignment properties. The right structure depends on what the partnership is actually trying to accomplish — and getting the structure wrong creates incentive misalignment that no amount of relationship management overcomes. Partnerships where pharma pays per-use for capability that scales unpredictably tend to produce financial surprises; partnerships where the partner is paid on milestones tied to evidence generation tend to align effort more reliably with pharma’s actual needs.

Operating Model and Integration

The operating model — how the partnership runs day to day — is where most executives stop paying attention and where most partnerships actually live or die. The deal team negotiates the contract; the operating teams have to live with it for years. Operating model design that treats execution as someone else’s problem produces partnerships that look great on paper and underperform in practice.

The operating model questions that matter most:

• Joint governance structure. Steering committee composition, cadence, decision rights, and escalation paths. Vague governance leads to slow decisions and avoidable conflict.
• Internal accountability. A single named owner inside pharma with authority and capacity to make the partnership work. “Co-ownership” between three functions reliably produces no ownership.
• Integration depth. How tightly the partner’s capability is woven into pharma’s processes, systems, and decision flows. Loose integration means low value capture; tight integration means high switching cost. The deliberate calibration matters.
• Resourcing realism. The pharma-side resources required to make the partnership work. Most partnerships are sized in the deal contemplation as needing a fraction of the resources they actually consume.
• Performance measurement. What metrics define success, who collects them, and how often they’re reviewed at a level senior enough to drive course correction.

The partnerships that perform are the ones where the operating model is designed with the same rigor as the contract — and where the operating model gets revisited annually as the partnership evolves. Partnerships that lock in their original operating model and never revisit it tend to drift; the original design rarely matches what the partnership actually needs after the first year of real-world experience.

Diligence Questions That Surface Real Signal

Standard diligence — financials, references, technology demos — captures less signal than the questions vendors are least prepared for. The questions worth investing in:

• “Walk me through your last failed pharma engagement. What happened, what did you learn, and what’s different now?”
• “Show me the validation documentation your most demanding pharma customer requires. What does it look like and how detailed is it?”
• “What’s your runway, and who controls the company? If your funding situation changes in twelve months, what’s the continuity plan for our partnership?”
• “How much of your engineering capacity goes to existing customer needs versus new product development? What’s the ratio for the past four quarters?”
• “Who are the three pharma customers we could speak with — including ones you haven’t pre-coached?”
• “When was the last material model or product change you pushed to all customers, and how much advance notice did affected customers receive?”
• “What’s your most common complaint from pharma customers in QBRs? What are you doing about it?”
• “Tell me about a recent pharma customer who didn’t renew, and why.”

Vendors who answer these questions concretely with documentation in hand pass an important threshold. Vendors who deflect, generalize, or promise to follow up have told you something important. The signal isn’t whether the answers are favorable — it’s whether the partner has the operational maturity to answer truthfully and specifically. Vendors who can’t, become partnerships that disappoint.

Post-Deal Practices That Determine Outcome

Diligence and contracting are necessary but not sufficient. Partnership performance is determined disproportionately by the post-deal management practices the pharma sponsor sustains. The practices that pay back consistently:

Quarterly business reviews with substance. Not status meetings — actual reviews of performance against the original case, roadmap evolution, risk indicators, and relationship health. The QBR is also where the operating model gets revisited and recalibrated based on real experience.

A named partnership owner with continuity. The single most powerful predictor of partnership outcomes is whether the same senior owner stays in the role for at least three years. Owner turnover is the leading cause of partnership drift; continuity is the leading cause of partnership compounding value.

Honest reporting against the case. The economic case made at signing should be revisited at least annually. Are the assumptions holding? Where are they not? What does that mean for the trajectory? Partnerships that quietly stop being measured against the original case tend to quietly stop delivering against it.

Active vendor portfolio management. The partnership doesn’t exist in isolation — it sits in a portfolio of digital health relationships that should be managed deliberately as a portfolio. Annual portfolio reviews surface concentration risk, gaps, and opportunities to consolidate or exit relationships that have stopped earning their place.

Willingness to exit when warranted. Pharma organizations that hold underperforming partnerships indefinitely teach their organizations that partnership decisions don’t require accountability. Pharma organizations that exit cleanly when the case stops holding teach the opposite — that partnerships are managed assets and that adding one creates an ongoing performance bar. The discipline of exit is a strategic capability, not a failure mode.

Digital health partnerships, done well, are among the most leveraged moves a pharma executive can make. Done poorly, they consume management attention, dilute strategy, and accumulate as portfolio drag. The difference between the two outcomes is mostly determined by the discipline applied at evaluation and sustained in management — both of which sit squarely within executive control.

The discipline of saying no

One executive practice that consistently differentiates pharma organizations with strong digital health portfolios from those with weak ones is the willingness to say no. Most pharma executives have more partnership opportunities flowing across their desks than the organization can absorb. The default behavior — accepting the deals that look interesting, deferring on the ones that don’t, and accumulating partnerships as they arrive — produces portfolios that are larger than they should be and weaker than they could be.

The corrective is to define the partnership portfolio strategy explicitly: what categories the organization is investing in, how many partnerships in each category make sense given management capacity, and what the criteria are for accepting versus declining. With the strategy defined, “no” becomes a defensible answer rather than a relationship-damaging rejection. Partners get clearer signal on what the organization is and isn’t pursuing, internal teams stop chasing deals that won’t ultimately get sponsored, and the portfolio that emerges is the result of deliberate construction rather than accumulated drift.

Pharma executives who have built durable partnership portfolios consistently report that the conversations they’re proudest of are the ones where they declined a deal that looked attractive on paper but didn’t fit the strategy. The discipline of saying no — visibly, with rationale, and at a level that signals organizational seriousness — is one of the highest-return executive behaviors in this domain.

References